Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2017 1
2018 1
2019 2
2020 6
2021 3
2022 7
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche.
Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho JW, Zhao X, Estivill G, Adam I, Sanchez X, McCarthy S, Schaller J, Khan Z, Ruzo A, Pastorello R, Richardson ET, Dillon D, Montero-Llopis P, Barroso-Sousa R, Forman J, Shukla SA, Tolaney SM, Mittendorf EA, von Andrian UH, Wucherpfennig KW, Hemberg M, Agudo J. Baldominos P, et al. Among authors: richardson et. Cell. 2022 May 12;185(10):1694-1708.e19. doi: 10.1016/j.cell.2022.03.033. Epub 2022 Apr 20. Cell. 2022. PMID: 35447074 Free article.
Salivary Gland-like Tumors of the Breast.
Richardson ET, Jo VY, Schnitt SJ. Richardson ET, et al. Arch Pathol Lab Med. 2023 Sep 1;147(9):1014-1024. doi: 10.5858/arpa.2023-0038-RA. Arch Pathol Lab Med. 2023. PMID: 37651394 Free article. Review.
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.
Barroso-Sousa R, Forman J, Collier K, Weber ZT, Jammihal TR, Kao KZ, Richardson ET 3rd, Keenan T, Cohen O, Manos MP, Brennick RC, Ott PA, Hodi FS, Dillon DA, Attaya V, O'Meara T, Lin NU, Van Allen EM, Rodig S, Winer EP, Mittendorf EA, Wu CJ, Wagle N, Stover DG, Shukla SA, Tolaney SM. Barroso-Sousa R, et al. Among authors: richardson et 3rd. JCO Precis Oncol. 2022 Jul;6:e2100413. doi: 10.1200/PO.21.00413. JCO Precis Oncol. 2022. PMID: 35797509 Free PMC article.
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer.
Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET 3rd, Attaya V, Anderson L, Mittendorf EA, Overmoyer B, Winer EP, Krop IE, Agudo J, Van Allen EM, Tolaney SM. Waks AG, et al. Among authors: richardson et 3rd. J Immunother Cancer. 2022 Oct;10(10):e005119. doi: 10.1136/jitc-2022-005119. J Immunother Cancer. 2022. PMID: 36252998 Free PMC article. Clinical Trial.
Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?
Castro P, Palomo M, Moreno-Castaño AB, Fernández S, Torramadé-Moix S, Pascual G, Martinez-Sanchez J, Richardson E, Téllez A, Nicolas JM, Carreras E, Richardson PG, Badimon JJ, Escolar G, Diaz-Ricart M. Castro P, et al. Among authors: richardson e. Cardiovasc Drugs Ther. 2022 Jun;36(3):547-560. doi: 10.1007/s10557-021-07207-w. Epub 2021 Jun 7. Cardiovasc Drugs Ther. 2022. PMID: 34097193 Free PMC article. Review.
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer.
Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, García-Pedrero J, Cañadas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn R. Hermida-Prado F, et al. Among authors: richardson et. Cancer Res. 2023 Oct 2;83(19):3284-3304. doi: 10.1158/0008-5472.CAN-23-1711. Cancer Res. 2023. PMID: 37450351 Free PMC article.
Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes.
Richardson E, García-Bernal D, Calabretta E, Jara R, Palomo M, Baron RM, Yanik G, Fareed J, Vlodavsky I, Iacobelli M, Díaz-Ricart M, Richardson PG, Carlo-Stella C, Moraleda JM. Richardson E, et al. Expert Opin Ther Targets. 2021 Jun;25(6):423-433. doi: 10.1080/14728222.2021.1944101. Epub 2021 Jun 25. Expert Opin Ther Targets. 2021. PMID: 34167431 Review.
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Lynce F, Stevens LE, Li Z, Brock JE, Gulvady A, Huang Y, Nakhlis F, Patel A, Force JM, Haddad TC, Ueno N, Stearns V, Wolff AC, Clark AS, Bellon JR, Richardson ET, Balko JM, Krop IE, Winer EP, Lange P, Hwang ES, King TA, Tolaney SM, Thompson A, Gupta GP, Mittendorf EA, Regan MM, Overmoyer B, Polyak K. Lynce F, et al. Among authors: richardson et. Breast Cancer Res. 2024 Jan 31;26(1):20. doi: 10.1186/s13058-024-01774-0. Breast Cancer Res. 2024. PMID: 38297352 Free PMC article. Clinical Trial.
26 results